Show simple item record

dc.contributor.authorMalin, Adam S
dc.contributor.authorHuygen, Kris
dc.contributor.authorContent, Jean
dc.contributor.authorMackett, Mike
dc.contributor.authorBrandt, Lisa
dc.contributor.authorAndersen, Peter
dc.contributor.authorSmith, Steven M
dc.contributor.authorDockrell, Hazel M
dc.date.accessioned2010-01-19T17:25:05Z
dc.date.available2010-01-19T17:25:05Z
dc.date.issued2000-11
dc.identifier.citationVaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85. 2000, 2 (14):1677-85 Microbes Infect.en
dc.identifier.issn1286-4579
dc.identifier.pmid11137041
dc.identifier.doi10.1016/S1286-4579(00)01323-X
dc.identifier.urihttp://hdl.handle.net/10541/90043
dc.description.abstractThere is increasing evidence to implicate a role for CD8(+) T cells in protective immunity against tuberculosis. Recombinant vaccinia (rVV) expressing Mycobacterium tuberculosis (MTB) proteins can be used both as tools to dissect CD8(+) T-cell responses and, in attenuated form, as candidate vaccines capable of inducing a balanced CD4(+)/CD8(+) T-cell response. A panel of rVV was constructed to express four immunodominant secreted proteins of MTB: 85A, 85B and 85C and ESAT-6. A parallel group of rVV was constructed to include the heterologous eukaryotic tissue plasminogen activator (tPA) signal sequence to assess if this would enhance expression and immunogenicity. Clear expression was obtained for 85A, 85B and ESAT-6 and the addition of tPA resulted in N-glycosylation and a 4-10-fold increase in expression. Female C57BL/6 mice were immunised using the rVV-Ag85 constructs, and interleukin-2 and gamma-interferon were assayed using a co-culture of immune splenocytes and recall antigen. There was a marked increase in cytokine production in mice immunised with the tPA-containing constructs. We report the first data demonstrating enhanced immunogenicity of rVV using a tPA signal sequence, which has significant implications for future vaccine design.
dc.language.isoenen
dc.subject.meshAcyltransferases
dc.subject.meshAnimals
dc.subject.meshAntigens, Bacterial
dc.subject.meshBacterial Proteins
dc.subject.meshBacterial Vaccines
dc.subject.meshBase Sequence
dc.subject.meshCells, Cultured
dc.subject.meshCloning, Molecular
dc.subject.meshCoculture Techniques
dc.subject.meshFemale
dc.subject.meshGenetic Vectors
dc.subject.meshGlycosylation
dc.subject.meshInterferon-gamma
dc.subject.meshInterleukin-2
dc.subject.meshMice
dc.subject.meshMice, Inbred C57BL
dc.subject.meshMolecular Sequence Data
dc.subject.meshMycobacterium tuberculosis
dc.subject.meshProtein Folding
dc.subject.meshSignal Recognition Particle
dc.subject.meshTissue Plasminogen Activator
dc.subject.meshVaccinia virus
dc.titleVaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85.en
dc.typeArticleen
dc.contributor.departmentImmunology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, WC1E 7HT, London, UK. adam.malin@bigfoot.comen
dc.identifier.journalMicrobes and Infectionen
html.description.abstractThere is increasing evidence to implicate a role for CD8(+) T cells in protective immunity against tuberculosis. Recombinant vaccinia (rVV) expressing Mycobacterium tuberculosis (MTB) proteins can be used both as tools to dissect CD8(+) T-cell responses and, in attenuated form, as candidate vaccines capable of inducing a balanced CD4(+)/CD8(+) T-cell response. A panel of rVV was constructed to express four immunodominant secreted proteins of MTB: 85A, 85B and 85C and ESAT-6. A parallel group of rVV was constructed to include the heterologous eukaryotic tissue plasminogen activator (tPA) signal sequence to assess if this would enhance expression and immunogenicity. Clear expression was obtained for 85A, 85B and ESAT-6 and the addition of tPA resulted in N-glycosylation and a 4-10-fold increase in expression. Female C57BL/6 mice were immunised using the rVV-Ag85 constructs, and interleukin-2 and gamma-interferon were assayed using a co-culture of immune splenocytes and recall antigen. There was a marked increase in cytokine production in mice immunised with the tPA-containing constructs. We report the first data demonstrating enhanced immunogenicity of rVV using a tPA signal sequence, which has significant implications for future vaccine design.


Files in this item

This item appears in the following Collection(s)

Show simple item record